
Breast Cancer Treatment by Stage (0–IV): A Clear Guide to the 2026 Guidelines
Breast cancer treatment by stage depends on two main factors: the stage of the disease (how large the tumor is, and whether it has spread to lymph nodes or other organs) and the type of cancer (hormone receptor–positive, HER2-positive or triple-negative). Stages 0–III are treated with the aim of cure, while stage IV aims to control the disease for as long as possible with good quality of life. At Namarak Hospital, our multidisciplinary team plans each patient's treatment according to the latest 2026 NCCN, ASCO and ESMO guidelines.
This article is an overview by stage. For details on each type, see HR+/HER2− · HER2-positive · HER2-low/ultralow · TNBC
What does the stage tell us?
Stage is determined by tumor size (T), lymph node involvement (N) and distant spread (M), together with tumor grade and receptor results (ER, PR, HER2), according to the AJCC 8th edition.
Stage 0 — cancer still confined to the milk ducts, not invasive (DCIS)
Stage I — small tumor (up to 2 cm), with no or only very minimal lymph node involvement
Stage II — tumor 2–5 cm, or spread to 1–3 axillary lymph nodes
Stage III — tumor larger than 5 cm, involving the skin or chest wall, or spread to many lymph nodes, including inflammatory breast cancer
Stage IV — spread to other organs such as bone, lung, liver or brain
Patients with early-stage disease and no symptoms do not need whole-body scans, but for stage III or when symptoms are present, the doctor will order additional tests to look for spread.
Stage 0 (DCIS) — cancer within the milk ducts
Surgery: breast-conserving surgery with radiation, or mastectomy; axillary surgery is not needed (except in some cases of mastectomy)
Radiation: reduces local recurrence; some low-risk patients may consider omitting it, based on the doctor's assessment together with the patient's decision
Endocrine therapy: considered for hormone receptor–positive DCIS to reduce recurrence and new cancer in the other breast
No chemotherapy is needed, and the chance of cure is very high
Stage I — early stage, small tumor
Most patients have surgery first, followed by additional treatment according to type and risk.
Surgery: breast-conserving surgery with radiation, or mastectomy, with sentinel lymph node biopsy; eligible patients may receive intraoperative radiotherapy (IORT)
HR+/HER2−: endocrine therapy for 5–10 years; genomic testing of the tumor guides the chemotherapy decision, and many patients do not need chemotherapy
HER2-positive: tumors 0.5–2 cm receive paclitaxel for 12 weeks with trastuzumab for 1 year; very small tumors are decided individually
TNBC: tumors larger than 1 cm usually receive treatment before surgery; smaller tumors are considered for chemotherapy individually
Stage II — larger tumor or lymph node spread
HR+/HER2−: surgery followed by endocrine therapy; chemotherapy according to risk or genomic testing, and a CDK4/6 inhibitor (abemaciclib or ribociclib) for higher-risk disease
HER2-positive: treatment before surgery is standard (chemotherapy with trastuzumab + pertuzumab, or T-DXd followed by THP), with post-surgical treatment chosen according to the response
TNBC: chemotherapy with pembrolizumab before surgery (KEYNOTE-522), with post-surgical treatment according to the response
Treatment before surgery shrinks the tumor, improves the chance of breast conservation and shows how well the disease responds
Stage III — locally advanced disease
This stage is still treated with the aim of cure, usually starting with treatment before surgery according to the cancer type, followed by surgery, radiation to the breast and lymph nodes, and post-surgical treatment.
Before surgery: regimens by type, such as KEYNOTE-522 for TNBC, HER2-targeted therapy for HER2-positive disease, and chemotherapy or endocrine therapy for HR+ disease
After surgery: if cancer remains, additional treatments include capecitabine or olaparib for TNBC, T-DM1 or T-DXd for HER2-positive disease, and CDK4/6 inhibitors for HR+ disease
Radiation: usually to the chest wall or breast and the regional lymph nodes
Inflammatory breast cancer: always treated with drugs first, followed by mastectomy with axillary dissection and radiation
Stage IV — metastatic disease
The goal is to control the disease for as long as possible with good quality of life, and many patients now live with the disease for years. The main treatment is systemic therapy chosen by type and biomarkers. When metastasis is first diagnosed, a biopsy should confirm it and the receptors should be re-tested.
HR+/HER2−: endocrine therapy with a CDK4/6 inhibitor first line, then drugs chosen by ESR1, PIK3CA and BRCA results, and ADCs
HER2-positive: THP followed by maintenance, or T-DXd + pertuzumab, then T-DXd or a tucatinib regimen in later lines
TNBC: chosen by PD-L1 — immunotherapy with chemotherapy or sacituzumab, or ADCs (Dato-DXd, sacituzumab) when immunotherapy cannot be used
HER2-low: T-DXd becomes an additional option after first-line treatment
Routine surgery on the breast or radiation to every metastatic site does not prolong survival. The NRG-BR002 trial (published October 2026) found that adding radiation or surgery to all metastases in patients with only a few sites of spread (oligometastasis) did not improve progression-free or overall survival, so these treatments are used mainly for symptom relief or in clinical trials. See Recurrent and metastatic breast cancer
Summary table by stage and type
Stage 0: surgery ± radiation ± endocrine therapy (no chemotherapy)
Stage I: surgery first → additional treatment by type (endocrine therapy / paclitaxel + trastuzumab / chemotherapy for TNBC >0.5–1 cm)
Stage II: HR+ surgery first + risk-based treatment · HER2-positive and TNBC treatment before surgery
Stage III: treatment before surgery → surgery → radiation → post-surgical treatment by response
Stage IV: systemic therapy by type and biomarkers + supportive care; local surgery/radiation when indicated
Important note: some new drugs are approved in the US or Europe but may not yet be registered or reimbursable in Thailand. Our team will explain the options that are actually available and the estimated costs.
Frequently asked questions (FAQ)
Which stages of breast cancer can be cured?
Stages 0 to III are treated with the aim of cure, with a high chance of cure especially in stages 0–I. Stage IV is usually not curable, but the disease can now be controlled for many years with drugs chosen according to the cancer type.
Why do some patients receive drugs before surgery while others have surgery first?
It depends on stage and type. Large tumors, lymph node spread, and HER2-positive or triple-negative cancers usually receive drugs first to shrink the tumor and assess the response, which guides treatment after surgery. Small or hormone receptor–positive tumors usually have surgery first.
Does stage 0 (DCIS) need chemotherapy?
No. DCIS is treated with surgery, possibly with radiation, and endocrine therapy for hormone receptor–positive disease. The chance of cure is very high.
Can the breast be operated on in stage IV?
Breast surgery in metastatic disease does not prolong survival for most patients. It is considered when there is a specific reason, such as an ulcerating or bleeding tumor, to relieve symptoms and improve quality of life.
Does everyone need whole-body scans?
Not in early-stage disease without symptoms. The doctor will order further tests for stage III or when symptoms suggest spread, such as bone pain, persistent cough or abnormal liver tests.
About Namarak Hospital
Namarak Hospital is a specialized breast hospital in Bangkok, where breast surgeons, medical oncologists, radiologists and pathologists plan treatment together as a multidisciplinary team according to the latest international guidelines. To discuss a treatment plan or request a second opinion, see Breast Cancer Treatment, Second Opinion, or contact us on LINE, tel. +66 2 059 0245.
Related treatment guides
References
NCCN Clinical Practice Guidelines in Oncology: Breast Cancer, Version 4.2026
AJCC Cancer Staging Manual, 8th Edition — Breast
Caswell-Jin JL, et al. ASCO Living Guideline, HR+/HER2− Stage I–III, Version 2026.1.0
de Azambuja E, et al. Metastatic breast cancer: ESMO Clinical Practice Guideline. Ann Oncol 2026
Chmura SJ, et al. NRG-BR002: Metastasis-directed therapy for oligometastatic breast cancer. J Clin Oncol, October 2026
Medically reviewed by: Namarak Hospital medical team · Guidelines checked: 16 November 2026 · This information is for general education and is not individual medical advice. Please consult your doctor for diagnosis and treatment suited to you.





Comments